Addition of IMP3 to L1CAM for discrimination between low- and
high-grade endometrial carcinomas: a European Network for
Individualised Treatment of Endometrial Cancer collaboration
study

J 2019

Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study

VISSER, Nicole C. M.; Louis J. M. VAN DER PUTTEN; Alex VAN EGERSCHOT; Koen K. VAN DE VIJVER; Maria SANTACANA et al.

Základní údaje

Originální název

Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study

Autoři

Vydání

Human pathology, Philadelphia, PA, W.B. Saunders Company, 2019, 0046-8177

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30109 Pathology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.735

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/19:00112954

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Endometrial carcinoma; Diagnostic biomarker; Prognostic biomarker; IMP3; L1CAM

Štítky

14110230, 14110411, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 2. 2020 08:55, Mgr. Tereza Miškechová

Anotace

V originále

Discrimination between low- and high-grade endometrial carcinomas (ECs) is clinically relevant but can be challenging for pathologists, with moderate interobserver agreement. Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is an oncofoetal protein that is associated with nonendometrioid endometrial carcinomas but has been limited studied in endometrioid carcinomas. The aim of this study is to investigate the diagnostic and prognostic value of IMP3 in the discrimination between low- and high-grade ECs and its added value to L1CAM. IMP3 and L1CAM expression was assessed in tumors from 378 patients treated for EC at 1 of 9 participating European Network for Individualised Treatment of Endometrial Cancer centers. IMP3 was expressed in 24.6% of the tumors. In general, IMP3 was more homogeneously expressed than L1CAM. IMP3 expression was significantly associated with advanced stage, nonendometrioid histology, grade 3 tumors, deep myometrial invasion, lymphovascular space invasion, distant recurrences, overall mortality, and disease-related mortality. Simultaneous absence of IMP3 and Ll CAM expression showed the highest accuracy for identifying low-grade carcinomas (area under the curve 0.766), whereas simultaneous expression of IMP3 and L1CAM was strongly associated with high-grade carcinomas (odds ratio 19.7; 95% confidence interval 9.2-42.2). Even within endometrioid carcinomas, this combination remained superior to IMP3 and L1CAM alone (odds ratio 8.6; 95% confidence interval 3.4-21.9). In conclusion, IMP3 has good diagnostic value and together with L1CAM represents the optimal combination of diagnostic markers for discrimination between low- and high-grade ECs compared to IMP3 and L1CAM alone. Because of the homogenous expression of IMP3, this marker might be valuable in preoperative biopsies when compared to the more patchy L1CAM expression. (C) 2019 Elsevier Inc. All rights reserved.

Citovat

VISSER, Nicole C. M.; Louis J. M. VAN DER PUTTEN; Alex VAN EGERSCHOT; Koen K. VAN DE VIJVER; Maria SANTACANA; Peter BRONSERT; Marc HIRSCHFELD; Eva COLAS; Antonio GIL-MORENO; Angel GARCIA; Gemma MANCEBO; Francesc ALAMEDA; Camilla KRAKSTAD; Ingvild L. TANGEN; Jutta HUVILA; Stefanie SCHRAUWEN; Martin KOSKAS; Francine WALKER; Vít WEINBERGER; Luboš MINÁŘ; Jitka HAUSNEROVÁ; Marc P. L. M. SNIJDERS; Saskia VAN DEN BERG-VAN ERP; Xavier MATIAS-GUIU; Jone TROVIK; Frederic AMANT; Leon F. A. G. MASSUGER; Johan BULTEN a Johanna M. A. PIJNENBORG. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Human pathology. Philadelphia, PA: W.B. Saunders Company, 2019, roč. 89, JUL 2019, s. 90-98. ISSN 0046-8177. Dostupné z: https://doi.org/10.1016/j.humpath.2019.04.014.

@article{1622896,
   author = {Visser, Nicole C. M. and van der Putten, Louis J. M. and van Egerschot, Alex and van de Vijver, Koen K. and Santacana, Maria and Bronsert, Peter and Hirschfeld, Marc and Colas, Eva and GilandMoreno, Antonio and Garcia, Angel and Mancebo, Gemma and Alameda, Francesc and Krakstad, Camilla and Tangen, Ingvild L. and Huvila, Jutta and Schrauwen, Stefanie and Koskas, Martin and Walker, Francine and Weinberger, Vít and Minář, Luboš and Hausnerová, Jitka and Snijders, Marc P. L. M. and van den Bergandvan Erp, Saskia and MatiasandGuiu, Xavier and Trovik, Jone and Amant, Frederic and Massuger, Leon F. A. G. and Bulten, Johan and Pijnenborg, Johanna M. A.},
   article_location = {Philadelphia, PA},
   article_number = {JUL 2019},
   doi = {https://doi.org/10.1016/j.humpath.2019.04.014},
   keywords = {Endometrial carcinoma; Diagnostic biomarker; Prognostic biomarker; IMP3; L1CAM},
   language = {eng},
   issn = {0046-8177},
   journal = {Human pathology},
   title = {Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study},
   url = {http://dx.doi.org/10.1016/j.humpath.2019.04.014},
   volume = {89},
   year = {2019}
}

TY  - JOUR
ID  - 1622896
AU  - Visser, Nicole C. M. - van der Putten, Louis J. M. - van Egerschot, Alex - van de Vijver, Koen K. - Santacana, Maria - Bronsert, Peter - Hirschfeld, Marc - Colas, Eva - Gil-Moreno, Antonio - Garcia, Angel - Mancebo, Gemma - Alameda, Francesc - Krakstad, Camilla - Tangen, Ingvild L. - Huvila, Jutta - Schrauwen, Stefanie - Koskas, Martin - Walker, Francine - Weinberger, Vít - Minář, Luboš - Hausnerová, Jitka - Snijders, Marc P. L. M. - van den Berg-van Erp, Saskia - Matias-Guiu, Xavier - Trovik, Jone - Amant, Frederic - Massuger, Leon F. A. G. - Bulten, Johan - Pijnenborg, Johanna M. A.
PY  - 2019
TI  - Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study
JF  - Human pathology
VL  - 89
IS  - JUL 2019
SP  - 90-98
EP  - 90-98
PB  - W.B. Saunders Company
SN  - 00468177
KW  - Endometrial carcinoma
KW  - Diagnostic biomarker
KW  - Prognostic biomarker
KW  - IMP3
KW  - L1CAM
UR  - http://dx.doi.org/10.1016/j.humpath.2019.04.014
L2  - http://dx.doi.org/10.1016/j.humpath.2019.04.014
N2  - Discrimination between low- and high-grade endometrial carcinomas (ECs) is clinically relevant but can be challenging for pathologists, with moderate interobserver agreement. Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is an oncofoetal protein that is associated with nonendometrioid endometrial carcinomas but has been limited studied in endometrioid carcinomas. The aim of this study is to investigate the diagnostic and prognostic value of IMP3 in the discrimination between low- and high-grade ECs and its added value to L1CAM. IMP3 and L1CAM expression was assessed in tumors from 378 patients treated for EC at 1 of 9 participating European Network for Individualised Treatment of Endometrial Cancer centers. IMP3 was expressed in 24.6% of the tumors. In general, IMP3 was more homogeneously expressed than L1CAM. IMP3 expression was significantly associated with advanced stage, nonendometrioid histology, grade 3 tumors, deep myometrial invasion, lymphovascular space invasion, distant recurrences, overall mortality, and disease-related mortality. Simultaneous absence of IMP3 and Ll CAM expression showed the highest accuracy for identifying low-grade carcinomas (area under the curve 0.766), whereas simultaneous expression of IMP3 and L1CAM was strongly associated with high-grade carcinomas (odds ratio 19.7; 95% confidence interval 9.2-42.2). Even within endometrioid carcinomas, this combination remained superior to IMP3 and L1CAM alone (odds ratio 8.6; 95% confidence interval 3.4-21.9). In conclusion, IMP3 has good diagnostic value and together with L1CAM represents the optimal combination of diagnostic markers for discrimination between low- and high-grade ECs compared to IMP3 and L1CAM alone. Because of the homogenous expression of IMP3, this marker might be valuable in preoperative biopsies when compared to the more patchy L1CAM expression. (C) 2019 Elsevier Inc. All rights reserved.
ER  -

VISSER, Nicole C. M.; Louis J. M. VAN DER PUTTEN; Alex VAN EGERSCHOT; Koen K. VAN DE VIJVER; Maria SANTACANA; Peter BRONSERT; Marc HIRSCHFELD; Eva COLAS; Antonio GIL-MORENO; Angel GARCIA; Gemma MANCEBO; Francesc ALAMEDA; Camilla KRAKSTAD; Ingvild L. TANGEN; Jutta HUVILA; Stefanie SCHRAUWEN; Martin KOSKAS; Francine WALKER; Vít WEINBERGER; Luboš MINÁŘ; Jitka HAUSNEROVÁ; Marc P. L. M. SNIJDERS; Saskia VAN DEN BERG-VAN ERP; Xavier MATIAS-GUIU; Jone TROVIK; Frederic AMANT; Leon F. A. G. MASSUGER; Johan BULTEN a Johanna M. A. PIJNENBORG. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. \textit{Human pathology}. Philadelphia, PA: W.B. Saunders Company, 2019, roč.~89, JUL 2019, s.~90-98. ISSN~0046-8177. Dostupné z: https://doi.org/10.1016/j.humpath.2019.04.014.

Přehled o publikaci